Tetraxis Therapeutics
United StatesAbout
Tetraxis Therapeutics is developing a novel tetra-receptor agonist platform for metabolic diseases, combining GLP-1R, GIPR, GcgR, and Y2R agonism to improve tolerability and efficacy in obesity and MASH treatment. The platform addresses the critical tolerability failure that prevents patients from reaching therapeutic doses of current GLP-1 therapies.
Products
Tetra-Receptor Agonist Platform
Novel tetra-receptor agonist chimera targeting GLP-1R, GIPR, GcgR, and Y2R for obesity and MASH treatment. The platform adds orthogonal satiety through PYY/Y2R activation, requiring lower GLP-1R intensity and reducing GI nausea burden while maintaining high efficacy. The 38-amino-acid peptide is a New Chemical Entity with composition of matter and method of treatment patents filed, following the 505(b)(1) NDA regulatory pathway.
Click to read more
Want to connect with this startup?
Sign up for FirstGlance to follow startups, save favorites, and connect with founders.
Sign up free